Comparative Pharmacology
Head-to-head clinical analysis: LASIX ONYU versus TORSEMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LASIX ONYU versus TORSEMIDE.
LASIX ONYU vs TORSEMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lasix (furosemide) inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption.
Torsemide inhibits the Na+/K+/2Cl- cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption, leading to increased urine output and decreased extracellular fluid volume.
Furosemide 20-80 mg IV/PO once or twice daily; max 600 mg/day for IV, 80 mg/day for PO.
Oral or intravenous: 5-20 mg once daily; may titrate up to 40 mg daily. Usual maintenance: 5-10 mg daily.
None Documented
None Documented
1.5-2.0 hours in normal renal function; prolonged to 10-15 hours in severe renal impairment (CrCl <10 mL/min); clinically significant accumulation risk with repeated dosing in renal disease.
Terminal elimination half-life is 3-4 hours in healthy adults; prolonged to 4-8 hours in cirrhosis and with advanced age. In renal failure (CrCl <30 mL/min), half-life may exceed 8 hours.
Primarily renal (50-80% as unchanged drug); biliary/fecal (20-30%); non-renal clearance accounts for up to 20%.
Approximately 80% renal (20% unchanged, 60% as metabolites, mainly glucuronide conjugate), 20% biliary/fecal. In renal impairment, clearance is reduced and half-life prolonged.
Category C
Category A/B
Loop Diuretic
Loop Diuretic